歐普康視(300595.SZ):硬性接觸鏡沖洗液獲得醫療器械首次註冊證
格隆匯3月21日丨歐普康視(300595.SZ)公佈,公司於近日獲得國家藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,產品名稱:硬性接觸鏡沖洗液。
硬性接觸鏡日常護理和保養中,對鏡片的沖洗是其中的一個護理環節,以提高鏡片清潔度、戴鏡安全性和舒適性。
硬鏡沖洗液有着較大的市場需求,公司一直在銷售消字號硬鏡沖洗液,市場上也有其它品牌的消字號硬鏡沖洗液。本次註冊,為境內首款三類醫療器械硬鏡沖洗液,在產品質量和質量管理體系上進一步升級。目前境內尚無其他硬鏡沖洗專用的三類醫療器械產品。同類產品在國內外硬鏡用户中廣泛使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.